نتائج البحث - "Rose, April A. N."

1

دورية أكاديمية

Clinical variables associated with immune checkpoint inhibitor outcomes in patients with metastatic urothelial carcinoma: a multicentre retrospective cohort study

المؤلفون: Labidi, Soumaya, Meti, Nicholas, Barua, Reeta, Li, Mengqi, Riromar, Jamila, Jiang, Di Maria, Fallah-Rad, Nazanin, Sridhar, Srikala S, Del Rincon, Sonia V, Pezo, Rossanna C, Ferrario, Cristiano, Cheng, Susanna, Sacher, Adrian G, Rose, April A N

المساهمون: Department of Medicine, University of Toronto, Fonds de Recherche du Québec - Santé, Fondation de l'Hôpital général juif

المصدر: BMJ Open ; volume 14, issue 3, page e081480 ; ISSN 2044-6055 2044-6055

مصطلحات موضوعية: General Medicine

الإتاحة: https://doi.org/10.1136/bmjopen-2023-081480Test

View record in BASE

2

دورية أكاديمية

Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases

المصدر: Lazaratos, Anna-Maria; Maritan, Sarah M; Quaiattini, Andrea; Darlix, Amélie; Ratosa, Ivica; Ferraro, Emanuela; Griguolo, Gaia; Guarneri, Valentina; Pellerino, Alessia; Hofer, Silvia; Jacot, William; Stemmler, Hans-Joachim; van den Broek, Marcel P H; Dobnikar, Nika; Panet, Francois; Lahijanian, Zubin; Morikawa, Aki; Seidman, Andrew D; Soffietti, Riccardo; Panasci, Lawrence; Petrecca, Kevin; Rose, April A N; Bouganim, Nathaniel; Dankner, Matthew (2023). Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases. Breast, 69:451-468.

مصطلحات موضوعية: Clinic for Neurology, 610 Medicine & health, General Medicine, Surgery, Breast cancer, Deruxtecan, Intrathecal, Leptomeningeal, Trastuzumab

وصف الملف: application/pdf

العلاقة: https://www.zora.uzh.ch/id/eprint/252373/1/PIIS0960977623004502.pdfTest; info:pmid/37156650; urn:issn:0960-9776

الإتاحة: https://doi.org/10.5167/uzh-25237310.1016/j.breast.2023.04.008Test
https://www.zora.uzh.ch/id/eprint/252373Test/
https://www.zora.uzh.ch/id/eprint/252373/1/PIIS0960977623004502.pdfTest

View record in BASE

النص الكامل

3

دورية أكاديمية

Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy

المؤلفون: Rajkumar, Shivshankari, Berry, Diana, Heney, Kayla A, Strong, Colton, Ramsay, LeeAnn, Lajoie, Mathieu, Alkallas, Rached, Nguyen, Tan-Trieu, Thomson, Cameron, Ahanfeshar-Adams, Mozhdeh, Dankner, Matthew, Petrella, Teresa, Rose, April A N, Siegel, Peter M, Watson, Ian R

المساهمون: T.H. Chan School of Medicine, Cameron Thomson

المصدر: Cell reports ; 39 ; 1 ; 110634 ; Canada ; United States

مصطلحات موضوعية: CP: Cancer, cell signaling, drug targets, kinase, melanoma, tumor suppressor

العلاقة: Cell Reports; https://doi.org/10.1016/j.celrep.2022.110634Test; Rajkumar S, Berry D, Heney KA, Strong C, Ramsay L, Lajoie M, Alkallas R, Nguyen TT, Thomson C, Ahanfeshar-Adams M, Dankner M, Petrella T, Rose AAN, Siegel PM, Watson IR. Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy. Cell Rep. 2022 Apr 5;39(1):110634. doi:10.1016/j.celrep.2022.110634. PMID: 35385748.; http://hdl.handle.net/20.500.14038/52472Test

الإتاحة: https://doi.org/10.1016/j.celrep.2022.110634Test
https://doi.org/20.500.14038/52472Test
https://hdl.handle.net/20.500.14038/52472Test

View record in BASE

النص الكامل